Lineage Cell Therapeutics (LCTX) Share-based Compensation (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Share-based Compensation of $40000.0 for Q1 2026, up 166.67% year-over-year from $15000.0 in Q1 2025, and up 101.1% quarter-over-quarter from -$3.6 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) Share-based Compensation (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Share-based Compensation history runs 17 years deep, the most recent figure standing at $40000.0 for Q1 2026.
- In Q1 2026, Share-based Compensation rose 166.67% year-over-year to $40000.0; the TTM figure through Mar 2026 stood at -$1.2 million (down 129.55% YoY), while the FY2025 annual figure was $6.2 million, down 24.39% from the prior year.
- Share-based Compensation for Q1 2026 stood at $40000.0, up from -$3.6 million in the prior quarter.
- The five-year high for Share-based Compensation was $1.3 million in Q3 2024, with the low at -$3.6 million in Q4 2025.
- The 5-year median for Share-based Compensation is $1.2 million (2024), against an average of $756352.9.
- The sharpest annual moves came in 2025 and 2026: Share-based Compensation slumped 376.65% in 2025, then jumped 166.67% in 2026.
- Lineage Cell Therapeutics' Share-based Compensation stood at $959000.0 in 2022, then increased by 10.53% to $1.1 million in 2023, then advanced by 24.06% to $1.3 million in 2024, then plunged by 376.65% to -$3.6 million in 2025, then soared by 101.1% to $40000.0 in 2026.
- Business Quant data shows LCTX's Share-based Compensation at $40000.0 in Q1 2026, -$3.6 million in Q4 2025, and $1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | 15.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.00 Mn |
| Jun 30, 2026 | 15.00 Mn |
| Mar 31, 2026 | 40,000.00 |
| Mar 31, 2026 | 40,000.00 |
| Dec 31, 2025 | -3.64 Mn |
| Dec 31, 2025 | -3.64 Mn |
| Sep 30, 2025 | 1.20 Mn |
| Sep 30, 2025 | 1.20 Mn |
| Jun 30, 2025 | 1.24 Mn |
| Jun 30, 2025 | 1.24 Mn |
| Mar 31, 2025 | 15,000.00 |
| Mar 31, 2025 | 15,000.00 |
| Dec 31, 2024 | 1.32 Mn |
| Dec 31, 2024 | 1.32 Mn |
| Sep 30, 2024 | 1.33 Mn |
| Sep 30, 2024 | 1.33 Mn |
| Jun 30, 2024 | 1.27 Mn |
| Jun 30, 2024 | 1.27 Mn |
| Mar 31, 2024 | 1.16 Mn |
| Mar 31, 2024 | 1.16 Mn |